Live Quote · NYSEANROHealthcare· Biotechnology

Alto Neuroscience, Inc.

$24.78 0.64%($-0.16)
TickerSpark Score
69/100
Solid
73
Valuation
20
Profitability
50
Growth
100
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANRO research report →

52-Week Range86% of range
Low
$2.28
Current
$24.78
High
$28.44
Company Overviewwww.altoneuroscience.com

About the company

Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder.

CEO
Amit Etkin
IPO
2024
Employees
76
HQ
Mountain View, CA, US

Price Chart

+977.39% · this period
$28.07$15.18$2.28Jul 02Dec 31Jul 02
Valuation
Market Cap
$869.63M
P/E
-10.97
P/S
0.00
P/B
3.35
EV/EBITDA
-8.58
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-47.22%
ROIC
20.70%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-63,238,000 · -2.94%
EPS
$-2.19 · 12.40%
Op Income
$-66,364,000
FCF YoY
-4.63%
Performance & Tape
52W High
$28.44
52W Low
$2.28
50D MA
$22.88
200D MA
$17.32
Beta
1.25
Avg Volume
408.22K

Get TickerSpark's AI analysis on ANRO

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
May 27, 26Miller Andrew Craigother26,000
May 27, 26Miller Andrew Craigother0
May 14, 26Etkin Amitother400,000
May 12, 26Sanchez Ramiroother10,958
May 12, 26Cox Christopher Nixonother10,958
May 12, 26Manji Husseiniother10,958
May 12, 26Dreyfus Andrewother10,958
May 12, 26York Gwillother10,958
Mar 1, 26Etkin Amitother6,227
Mar 1, 26Smith Nicholas Conradother2,806
Coverage · ANRO

Our ANRO coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on ANRO yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate ANRO report →
Internal Compare

Similar companies

Peers in the same neighborhood.